Man Group
ESPR

Man Group’s Esperion Therapeutics ESPR Stock Holding History

Man Group’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-339,775
Closed -$931K – 2426
2026
Q1 		$931K Buy
+339,775
New +$1.08M ﹤0.01% 1862
2024
Q4 		– Sell
-25,692
Closed -$42.4K – 2044
2024
Q3 		$42.4K Buy
+25,692
New +$51.9K ﹤0.01% 1925
2024
Q2 		– Sell
-440,770
Closed -$1.18M – 2089
2024
Q1 		$1.18M Buy
440,770
+223,785
+103% +$544K ﹤0.01% 1488
2023
Q4 		$649K Buy
+216,985
New +$281K ﹤0.01% 1588
2023
Q3 		– Sell
-117,251
Closed -$170K – 1866
2023
Q2 		$163K Buy
+117,251
New +$164K ﹤0.01% 1845
2023
Q1 		– Sell
-18,100
Closed -$93.4K – 1948
2022
Q4 		$113K Buy
+18,100
New +$129K ﹤0.01% 1891
2022
Q2 		– Sell
-112,903
Closed -$640K – 1724
2022
Q1 		$524K Buy
+112,903
New +$484K ﹤0.01% 1569
2021
Q4 		– Sell
-15,756
Closed -$190K – 1998
2021
Q3 		$190K Buy
15,756
+1,978
+14% +$28.8K ﹤0.01% 1768
2021
Q2 		$291K Sell
13,778
-14,248
-51% -$343K ﹤0.01% 1683
2021
Q1 		$786K Sell
28,026
-9,554
-25% -$282K ﹤0.01% 1356
2020
Q4 		$977K Buy
37,580
+19,969
+113% +$598K ﹤0.01% 1419
2020
Q3 		$655K Buy
17,611
+281
+2% +$11.1K ﹤0.01% 1484
2020
Q2 		$889K Buy
17,330
+10,992
+173% +$460K ﹤0.01% 1309
2020
Q1 		$200K Sell
6,338
-276,658
-98% -$14.6M ﹤0.01% 1470
2019
Q4 		$16.9M Buy
282,996
+76,369
+37% +$3.43M 0.06% 419
2019
Q3 		$7.58M Sell
206,627
-52,056
-20% -$2.06M 0.03% 685
2019
Q2 		$12M Buy
258,683
+24,566
+10% +$1.15M 0.04% 544
2019
Q1 		$9.4M Buy
234,117
+70,331
+43% +$3.15M 0.04% 603
2018
Q4 		$7.54M Buy
163,786
+20,218
+14% +$974K 0.03% 571
2018
Q3 		$6.37M Buy
143,568
+120,357
+519% +$5.53M 0.02% 859
2018
Q2 		$910K Buy
+23,211
New +$1.17M ﹤0.01% 1631

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Man Group's ESPR Position: Q2 2026 in Review

Man Group sold out of Esperion Therapeutics (ESPR) in Q2 2026, closing a stake of 339,775 shares — an estimated $931K sold.

Man Group first reported a position in ESPR in Q2 2018 and held it in 21 quarters. The position peaked at $16.9M in Q4 2019. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Man Group reported no remaining Esperion Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Man Group sold 339,775 Esperion Therapeutics shares in Q2 2026, an estimated $931K.
  • Man Group first reported a position in Esperion Therapeutics in Q2 2018 and held it in 21 quarters.
  • Man Group's Esperion Therapeutics position peaked at $16.9M in Q4 2019.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.